
[Interview] HLB preps FDA bid to unseat Oxervate with new eye drop
HLB Therapeutics is preparing to file for FDA approval of an eye drop it says can beat a $110,000 market incumbent on price, convenience, and clinical reach. The drug, RGN-259, targets neurotrophic keratopathy (NK), a rare degenerative eye disease caused …